RedDress
RedDress is an Israeli-founded medical device company that develops and sells the ActiGraft family of FDA-cleared, autologous point-of-care wound care systems, which create therapeutic blood clots from a patient's own blood to treat chronic wounds, serving US hospitals, VA facilities, wound care centers, and international distributors across 40+ countries.
- Company typePrivate
- Founded2009
- HeadquartersTel Aviv, Israel
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What RedDress does
RedDress is an Israel-headquartered medical device company (founded 2009 by Dr. Igal Kushnir and Alon Kushnir) that develops and commercializes the ActiGraft family of autologous wound care systems. Its core technology creates a therapeutic whole blood clot at the point of care by mixing a patient's own peripheral blood with a proprietary calcium gluconate coagulation agent, producing a wound matrix in under five minutes without a centrifuge, capital equipment, or HCT/P regulatory burden. The product line spans the original ActiGraft, ActiGraft+, and the current flagship ActiGraft PRO, with seven granted US patents and additional international filings protecting the chemistry and process. The company has secured FDA 510(k) clearance, CE Mark, and Medicare National Coverage Determination 270.3 with dedicated G-codes (G-0465 and G-0460) reimbursing providers approximately $1,829 per application for up to 20 applications per patient course in hospital outpatient and wound care settings.
The commercial model is a hybrid of direct enterprise field sales to wound care centers, hospitals, and podiatry practices, layered with multi-channel distribution: six US GPO contracts (Vizient, Premier, Capstone Health Alliance, MediGroup, Healogics iSupply, and Wound Care Advantage Formulary), a Federal Supply Schedule contract via Marathon Medical covering 1,300+ VA facilities, international distributor agreements spanning 40+ countries (notably OneMed for the Nordics), and resellers including Legacy Medical Consultants. US box pricing is approximately $4,000 per five-unit box, with per-application Medicare reimbursement of ~$1,829. End customers include academic medical centers (UF Health, UPMC, UNC Health, UCSF), the Veterans Health Administration, Healogics wound care centers (600+ nationally), and long-term/post-acute care facilities.
The clinical case is anchored in an RCT published in the Journal of Wound Care (September 2024) demonstrating 51% complete wound closure at 12 weeks for ActiGraft Pro versus 18% for standard of care (2.73x greater odds of healing), with prior data showing 72% closure in diabetic foot ulcers. More than 7,000 patients have been treated across the US and 30+ international markets since FDA clearance and CE Mark in 2020. The company has raised $43 million cumulatively, including a $26 million Series D in May 2023, and operates with 11-50 employees.
RedDress firmographics
Firmographics- Name
- RedDress
- Legal name
- RedDress USA, Inc.
- Website
- https://reddressmedical.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- RedDress is an Israeli-founded medical device company that develops and sells the ActiGraft family of FDA-cleared, autologous point-of-care wound care systems, which create therapeutic blood clots from a patient's own blood to treat chronic wounds, serving US hospitals, VA facilities, wound care centers, and international distributors across 40+ countries.
- Ownership category
- akta.pro rank
RedDress industry classification
Industry- Product category
- Advanced Wound Care
- NAICS
- Medical Equipment and Supplies Manufacturing (3391), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)
- akta.pro secondary industry
- Wound Care & Ulcer Management (HLAKACAN)
Keywords
Where RedDress is headquartered
LocationHeadquarters
- HQ city
- Tel Aviv
- HQ country
- Israel
- HQ region
- Middle East
Offices3 records
Markets served
RedDress business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
Revenue model
- ActiGraft Product Sales: Direct product sales of ActiGraft, ActiGraft+, and ActiGraft PRO systems to healthcare providers, wound care centers, hospitals, and through distribution partners. Products sold in boxes/units with per-application pricing.
- Medicare and Insurance Reimbursement: Eligible for national reimbursement from Medicare and Medicare Advantage via NCD 270.3 and G-codes (G-0465 & G-0460). Reimbursement covers procedure for diabetic patients with lower extremity chronic wounds.
- International Distribution: Revenue from international distribution partnerships in 40+ countries across five continents including Brazil, Canada, Hong Kong, India, Mexico, Turkey, UAE, South Africa, Ireland, Italy, and Nordic countries through OneMed partnership.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | ActiGraft PRO - Outpatient/Wound Care Center pricing |
| Transaction based/ take rate | Pay-as-you-go | Medicare Hospital Outpatient Facility (HOPD) reimbursement |
Go-to-market motion3 records
Distribution channels11 records
Marketing channels6 records
RedDress product offering
Product offeringCore offering
RedDress develops and sells FDA-cleared autologous wound management systems (ActiGraft, ActiGraft+, ActiGraft PRO) that transform a patient's own peripheral blood into a whole blood clot at the point of care for the treatment of chronic, non-healing wounds. Their proprietary technology uses a calcium gluconate coagulation powder to create therapeutic blood clots at the bedside in under five minutes, without requiring a centrifuge or capital equipment. Products are sold to hospitals, wound care centers, podiatrists, and long-term care facilities with Medicare reimbursement eligibility in the US.
Product overview
RedDress offers a suite of autologous wound care products based on proprietary patented technology that recreates the natural wound healing process using a patient's own blood. The product portfolio includes ActiGraft PRO (the most advanced version), ActiGraft+, and the original ActiGraft system, all enabling healthcare providers to produce in vitro blood clots from patient whole blood for application to chronic wounds. The systems are designed for point-of-care use, with ActiGraft PRO creating blood clots in under five minutes. These products treat various chronic wound types including diabetic foot ulcers, venous ulcers, pressure injuries, traumatic wounds, and post-surgical wounds. A specialized pilonidal sinus treatment protocol is also offered using the ActiGraft technology.
Differentiator
Problem solved
Functional benefit
Products and services
- ActiGraft PRO Most advanced autologous point-of-care wound management system, creating a whole blood clot at the patient's bedside in under five minutes by mixing fresh whole blood with proprietary coagulation powder. Used by healthcare providers for treatment of diabetic foot ulcers, venous ulcers, pressure injuries, traumatic wounds, post-surgical wounds, and skin tears.
- ActiGraft+ Enhanced wound management system featuring proprietary calcium gluconate powder to create whole blood clot. Designed to shorten coagulation time and produce higher-quality topically applied blood clot compared to original ActiGraft system.
- ActiGraft (Original System) Original FDA-cleared autologous wound care system that enables healthcare providers to produce in real time in vitro blood clots from a patient's whole blood for management of exuding cutaneous wounds.
- Pilonidal Sinus Treatment Specialized treatment protocol using ActiGraft for pilonidal sinus wounds, utilizing the autologous blood clot technology to promote healing in this specific wound type.
Quantifiable outcome
- 72% complete wound closure rate in diabetic patients within 12 weeks
- +5 more outcomes
Companies that use RedDress
Customer profileNamed customers8 records
Segments4 records
Ideal customer profiles5 records
RedDress technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
RedDress partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered minor and core.
- Legacy Medical ConsultantsminorLegacy Medical Consultants acquired right to sell RedDress ActiGraft Pro, broadening its strong wound care portfolio beyond allografts.
- Wound Care Advantage (WCA)minorActiGraft Pro added to WCA Formulary after comprehensive evaluation by WCA Product Council. WCA supports a national network of wound centers focused on reducing costs and improving patient outcomes.
- Healogics iSupplycoreActiGraft Pro selected by Healogics Wound Care Supply for addition to its iSupply GPO. Healogics operates over 600 wound care centers nationally and partners with 300+ skilled nursing facilities.
- OneMedcoreStrategic partnership with OneMed (part of Asker Healthcare Group) for exclusive commercialization and distribution of the ActiGraft wound care system in Finland and the Nordic region. Follows extensive product evaluation assessment.
- VizientcoreInnovative Technology contract with Vizient, the nation's leading healthcare performance improvement company serving more than half of US health care organizations. Contract awarded based on recommendation by hospital experts serving on Vizient's member-led councils.
- International Distribution PartnerscoreActive commercial agreements in 40+ countries across five continents including Brazil, Canada, Hong Kong, India, Mexico, Russia, Turkey, UAE, South Africa, Ireland, Italy, and UK. RedDress continues expanding global availability.
- GraftIn and SlavaMed (Ukraine)minorPartner medical specialists coordinating delivery of 400 ActiGraft systems donated to Ukrainian hospitals for treating civilian casualties from Russian attacks.
- Dr. Arkadiy Savchenko (Ukraine)minorLeading expert and Department Surgery No. 2 of Danylo Halytsky Lviv National Medical University, leading training of Ukrainian nurses, doctors and aid workers on how to use ActiGraft systems.
- Premier Inc.coreGroup purchasing agreement with Premier Inc., a leading healthcare improvement company uniting approximately 4,400 U.S. hospitals and more than 225,000 other providers. Allows Premier members to access RedDress' ActiGraft wound care product.
- MediGroupminorStrategic partnership with MediGroup, one of the nation's largest non-acute care GPOs representing physician centers, surgery centers, and specialty clinics. MediGroup has 25,000+ members representing over 200,000 physicians.
- European Distribution Partners (12 countries)coreStrategic distribution agreements in 12 European countries: Austria, Cyprus, Czech Republic, Germany, Greece, Poland, Romania, Slovakia, Slovenia, Switzerland, Turkey, and Ukraine to distribute CE-marked ActiGraft system.
- Capstone Health AllianceminorContract with Capstone Health Alliance, one of the nation's largest regional group purchasing organizations representing 300 hospitals in all 50 U.S. states. Enables expansion among regional healthcare providers.
- Marathon Medical (Federal Supply Schedule)coreContract with Marathon Medical allows RedDress to make ActiGraft available at veteran health facilities and other federal health facilities through the Federal Supply Schedule (FSS). VA system has over 1,300 facilities including VA Medical Centers and Outpatient Clinics.
Scale indicators12 records
Recent moves10 records
Expansion highlights6 records
RedDress competitors and assessment
Company assessmentDirect peers
- Organogenesis Holdings: Public advanced wound care and regenerative medicine company (NASDAQ: ORGO) selling skin substitute and biologic wound care products (Apligraf, Dermagraft, PuraPly) used to treat chronic wounds including diabetic foot ulcers. Direct competitor in the autologous/regenerative wound care category and the closest publicly traded comparable to RedDress's ActiGraft.
- MiMedx Group: Public regenerative medicine company (NASDAQ: MDXG) selling dehydrated human amnion/chorion membrane allografts (EpiFix, AmnioFix) for chronic wound care and surgical recovery. Closely comparable to RedDress in targeting diabetic foot ulcers with biologic regenerative technology through wound care center and podiatry channels.
Broad incumbents
- Smith+Nephew: Global medical device company (NYSE: SNN) with a large Advanced Wound Management division selling traditional dressings, NPWT (PICO, RENASYS), and skin substitutes. Broad incumbent offering overlapping solutions across hospital, wound care center, and home health settings where RedDress sells ActiGraft.
- ConvaTec Group: Public wound and ostomy care company (LON: CTEC) with advanced wound care products (AQUACEL, Granulox) and a sizable US wound care salesforce. Comparable to RedDress in targeting chronic wounds across hospital and home health channels, though much broader portfolio.
- Integra LifeSciences: Public medical technology company (NASDAQ: IART) with a Tissue Technologies segment selling regenerative wound care matrices (Integra Dermal Regeneration Template, PriMatrix, AmnioExcel). Comparable to RedDress in selling skin substitutes/biologic wound matrices to wound care centers and hospitals.
- Coloplast: Danish medical device company (CPH: COLO-B) with a Wound & Skin Care division selling Biatain dressings and a range of advanced wound care products. Comparable to RedDress in addressing chronic wounds (including diabetic foot ulcers) across healthcare providers, though broader portfolio.
- 3M Health Care (Solventum/KCI): 3M's Health Care business (and the spun-off Solventum with the KCI franchise) is the global NPWT leader (V.A.C. Therapy) and a dominant incumbent in advanced wound care. Comparable to RedDress as the incumbent category leader whose NPWT business ActiGraft can substitute or complement in hospital outpatient wound care.
Regional players
- Healogics: US-focused wound care services company operating 600+ hospital-partnered wound care centers and the iSupply GPO used by RedDress. Comparable as the dominant wound care center operator where ActiGraft is being adopted, with significant commercial influence over formulary choices.
Emerging players
- PolarityTE: Regenerative medicine company (NASDAQ: PTE) developing autologous skin regeneration products (SkinTE) for chronic wounds and burns. Comparable to RedDress in using an autologous, point-of-care tissue-based approach in wound healing, though smaller and earlier-stage in commercial scale.
- Amniox Medical: Subsidiary of TissueTech selling CLARIX and NEOX amniotic membrane wound care products for chronic and surgical wounds. Comparable to RedDress in selling biologic regenerative wound care products targeting podiatrists and wound care centers treating diabetic foot ulcers and other chronic wounds.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key highlights7 records
Customer concentration
RedDress social profiles
Digital presenceRedDress compliance and trust
Trust signalCompliance4 records
RedDress financial estimates
Financial estimateRevenue estimate
Valuation estimate
RedDress leadership team
Management profileNumber of profiles
Profiles5 records
RedDress funding detail
Funding detailFunding overview
Funding rounds2 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RedDress M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RedDress
What does RedDress do?
RedDress develops and sells FDA-cleared autologous wound management systems (ActiGraft, ActiGraft+, ActiGraft PRO) that transform a patient's own peripheral blood into a whole blood clot at the point of care for the treatment of chronic, non-healing wounds. Their proprietary technology uses a calcium gluconate coagulation powder to create therapeutic blood clots at the bedside in under five minutes, without requiring a centrifuge or capital equipment. Products are sold to hospitals, wound care centers, podiatrists, and long-term care facilities with Medicare reimbursement eligibility in the US.
Is RedDress a public or private company?
RedDress is a private company. It is classified as venture growth investor backed and is currently operating.
When was RedDress founded?
RedDress was founded in 2009. It employs 11 to 50 people.
Where is RedDress based?
RedDress is headquartered in Tel Aviv, Israel, in the Middle East region.
How does RedDress make money?
Three revenue lines are on record. ActiGraft Product Sales are the primary driver. The others are medicare and Insurance Reimbursement and international Distribution.
Who are RedDress's main competitors?
Direct peers on record are Organogenesis Holdings and MiMedx Group. Broad incumbents are Smith+Nephew, ConvaTec Group, Integra LifeSciences, Coloplast and 3M Health Care (Solventum/KCI). Healogics is listed as a regional player. Emerging players are PolarityTE and Amniox Medical.
Does RedDress have an API?
No public API is recorded for RedDress.
What industry is RedDress in?
RedDress's product category is Advanced Wound Care. Its primary akta.pro industry code is HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts), with a secondary code of HLAKACAN, Wound Care & Ulcer Management. Its NAICS code is 3391 and its SIC code is 3841.